Table 3 Correlation between pre-treatment circulating angiogenesis-related biomarkers and survival outcomes in studies which recruited patients with metastatic colorectal cancer [22,23,24]
Study Title | No. of patients | Treatment received | Pre-treatment biomarker | Correlation with survival outcomes |
|---|---|---|---|---|
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapya [22] | 582 | FOLFOX or CAPOX chemotherapy + cediranib/placebo | VEGF-D | Low pre-treatment concentration correlated with improved PFS and OS regardless of treatment received |
VEGFR-1 | ||||
VEGFR-3 | ||||
Tie-2 | ||||
Ang2 | No correlation | |||
Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer [23] | 90 | Camptothecin | VEGF-165 | Patients with high pre-treatment concentration were more likely to have progressive disease during treatment |
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance [24] | 43 | FOLFIRI + bevacizumab | VEGF-2 | No correlation |